Sex: M
Vaccine: COVID19-2
Symptoms: Ageusia, COVID-19, Dysgeusia
Clinical narrative: I had a loss of taste; I have a metallic taste in my mouth; COVID-19; This spontaneous case was reported by a patient and describes the occurrence of AGEUSIA (I had a loss of taste), DYSGEUSIA (I have a metallic taste in my mouth) and COVID-19 (COVID-19) in an elderly male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     Concurrent medical conditions included Type 1 diabetes mellitus and Heart disorder.   On 08-Jun-2023, the patient received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form and third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. In March 2023, the patient experienced COVID-19 (COVID-19). In June 2023, the patient experienced AGEUSIA (I had a loss of taste) and DYSGEUSIA (I have a metallic taste in my mouth). At the time of the report, AGEUSIA (I had a loss of taste) and DYSGEUSIA (I have a metallic taste in my mouth) had not resolved and COVID-19 (COVID-19) had resolved.            No concomitant medication was reported. The patient did not  receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. It was reported that the patient took 2 primary doses and 4 additional booster doses. The patient had the original and several boosters of Moderna vaccine. No PQC was mentioned.  Patient wanted to report this side effect since literature states that this was a rare side affect. It's been 11 days and I don't show any signs of improvement.  No treatment medication was reported. The patient stated that he had COVID-19 in March 2023. He reported that he did not have loss of taste and experienced fatigue, body aches and loss of appetite for a few days. No hospitalization was required.  Company Comment: This spontaneous case report concerns an elderly male patient with relevant medical history of Type 1 diabetes mellitus, who experienced non serious unexpected events of Ageusia (adverse event of special interest), Dysgeusia and COVID-19. Reportedly, immediately on same day or the next day after vaccination with the mRNA-1273.222 vaccine (bivalent dose, as sixth dose in vaccination schedule), the patient had a loss of taste and also he reported to have a metallic taste in his mouth. These events did not occur after vaccination with any of the previous doses of mRNA-1273 vaccine, as stated. The patient received  2 primary doses 4 additional booster doses in total. It was also reported that patient got COVID-19 infection, but it was not specified after which booster dose the patient had COVID-19 (to be confirmed). Symptoms of COVID-19 infection included fatigue, body aches and loss of appetite and lasted for a few days. It was confirmed that the patient did not require hospitalization due to COVID-19. At the time of this report, the events of Ageusia and Dysgeusia were still ongoing and no additional details regarding clinical course or laboratory investigations were provided at the time of this report. Recent COVID-19 infection and Type 1 diabetes mellitus are could be confounders for Ageusia and Dysgeusia. No further details were available for medical assessment. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-729761 (Linked Report).; Sender's Comments: This spontaneous case report concerns an elderly male patient with relevant medical history of Type 1 diabetes mellitus, who experienced non serious unexpected events of Ageusia (adverse event of special interest), Dysgeusia and COVID-19. Reportedly, immediately on same day or the next day after vaccination with the mRNA-1273.222 vaccine (bivalent dose, as sixth dose in vaccination schedule), the patient had a loss of taste and also he reported to have a metallic taste in his mouth. These events did not occur after vaccination with any of the previous doses of mRNA-1273 vaccine, as stated. The patient received  2 primary doses 4 additional booster doses in total. It was also reported that patient got COVID-19 infection, but it was not specified after which booster dose the patient had COVID-19 (to be confirmed). Symptoms of COVID-19 infection included fatigue, body aches and loss of appetite and lasted for a few days. It was confirmed that the patient did not require hospitalization due to COVID-19. At the time of this report, the events of Ageusia and Dysgeusia were still ongoing and no additional details regarding clinical course or laboratory investigations were provided at the time of this report. Recent COVID-19 infection and Type 1 diabetes mellitus are could be confounders for Ageusia and Dysgeusia. No further details were available for medical assessment. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report. US-MODERNATX, INC.-MOD-2023-729761:same reporter(Patint's wife)